Anti-IL-2R alpha (CD25) [Basiliximab]

Absolute Antibody

Anti-IL-2R alpha (CD25) [Basiliximab]

9

Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction

Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1kappa constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, Neutralisation/Blocking

Research Use Only

Monoclonal

Basiliximab

IL2RA

interleukin 2 receptor subunit alpha

CD25; IDDM10; IL-2 receptor subunit alpha; IL2R; IL-2R subunit alpha; IMD41; interleukin 2 receptor, alpha; interleukin-2 receptor subunit alpha; p55; TAC antigen; TCGFR

Human

IgG1

Interleukin-2 receptor subunit alpha

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Human, Monkey, Primate

-20°C,2°C to 8°C

12352203